D. Boral Capital Reaffirms “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI)

D. Boral Capital reiterated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $21.00 price objective on the stock.

TRVI has been the topic of a number of other reports. HC Wainwright increased their price target on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the stock a “buy” rating in a report on Monday, March 10th. Needham & Company LLC lowered their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Finally, Oppenheimer increased their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Seven analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $17.56.

Trevi Therapeutics Stock Down 2.1 %

Shares of TRVI opened at $6.47 on Wednesday. The company has a market capitalization of $497.32 million, a price-to-earnings ratio of -14.70 and a beta of 0.90. Trevi Therapeutics has a 52 week low of $2.30 and a 52 week high of $7.39. The stock’s 50-day moving average price is $4.60 and its 200-day moving average price is $3.75.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. As a group, equities analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Insider Activity at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares of the company’s stock, valued at approximately $519,075. This represents a 51.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 24.37% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Trevi Therapeutics

A number of large investors have recently modified their holdings of TRVI. Summit Investment Advisors Inc. lifted its stake in shares of Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after buying an additional 2,894 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after acquiring an additional 6,764 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Trevi Therapeutics in the 4th quarter valued at about $49,000. Squarepoint Ops LLC purchased a new position in Trevi Therapeutics in the 4th quarter worth approximately $58,000. Finally, Intech Investment Management LLC acquired a new position in shares of Trevi Therapeutics during the 3rd quarter worth approximately $63,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.